Fibromyalgia in Older Individuals.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
07
06
2021
pubmed:
9
7
2021
medline:
25
2
2023
entrez:
8
7
2021
Statut:
ppublish
Résumé
Fibromyalgia (FM) is a condition of chronic widespread pain (CWP) that can occur throughout the life cycle and is likely underrecognized in older patients. FM is associated with considerable suffering and reduction in quality of life and may occur as a unique condition, but in older patients is most likely to be associated with another medical illness. Understood mechanistically to be a sensitization of the nervous system, recently identified as nociplastic pain, FM is accepted as a valid medical illness that requires a positive diagnosis and directed treatments. The cornerstone of treatments for FM are nonpharmacologic interventions, with the understanding that medications provide only modest benefit for most patients, and with particular concern about adverse effects in older patients. If FM is not recognized, treatments may be misdirected to the other medical condition, with failure to address FM symptoms, leading to overall poor outcome. In contrast, new complaints in older patients should not immediately be attributed to FM, and physicians should be vigilant to ensure that onset of a new illness is not ignored. As FM is most often a lifelong condition, patients should be encouraged to identify their own personal strategies that can attenuate symptoms, especially when symptoms flare. Continued life participation should be the outcome goal.
Identifiants
pubmed: 34236617
doi: 10.1007/s40266-021-00879-x
pii: 10.1007/s40266-021-00879-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
735-749Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–55.
pubmed: 24737367
doi: 10.1001/jama.2014.3266
pmcid: 24737367
Arnold LM, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611–28.
pubmed: 30453109
doi: 10.1016/j.jpain.2018.10.008
pmcid: 30453109
Fitzcharles MA, Perrot S, Hauser W. Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain. 2018;22(9):1565–76.
pubmed: 29802812
doi: 10.1002/ejp.1252
pmcid: 29802812
Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356–62.
pubmed: 23801009
doi: 10.1007/s11916-013-0356-5
pmcid: 23801009
Defillo-Draiby JC, Page JS. Fibromyalgia syndrome, a geriatric challenge. R I Med J (2013). 2016;99(12):41–4.
Wolfe F, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.
pubmed: 7818567
doi: 10.1002/art.1780380104
pmcid: 7818567
Walitt B, et al. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS ONE. 2015;10(9): e0138024.
pubmed: 26379048
pmcid: 4575027
doi: 10.1371/journal.pone.0138024
Yunus MB, et al. Fibromyalgia syndrome among the elderly. Comparison with younger patients. J Am Geriatr Soc. 1988;36(11):987–95.
pubmed: 3171051
doi: 10.1111/j.1532-5415.1988.tb04364.x
pmcid: 3171051
Torma LM, et al. Growing old with fibromyalgia: factors that predict physical function. Nurs Res. 2013;62(1):16–24.
pubmed: 23114794
doi: 10.1097/NNR.0b013e318273b853
pmcid: 23114794
Pautex S, Cedraschi C, Allaz AF. Characteristics of elderly patients with fibromyalgia: a pilot retrospective study. Aging Clin Exp Res. 2012;24(5):490–4.
pubmed: 22732355
pmcid: 22732355
Su CH, et al. Increased risk of coronary heart disease in patients with primary fibromyalgia and those with concomitant comorbidity: a Taiwanese population-based cohort study. PLoS ONE. 2015;10(9): e0137137.
pubmed: 26366998
pmcid: 4569466
doi: 10.1371/journal.pone.0137137
Tzeng NS, et al. Fibromyalgia and risk of dementia-a nationwide, population-based cohort study. Am J Med Sci. 2018;355(2):153–61.
pubmed: 29406043
doi: 10.1016/j.amjms.2017.09.002
pmcid: 29406043
López-Ruiz M, et al. Central sensitization in knee osteoarthritis and fibromyalgia: beyond depression and anxiety. PLoS ONE. 2019;14(12): e0225836.
pubmed: 31805099
pmcid: 6894784
doi: 10.1371/journal.pone.0225836
Fitzcharles M, Cohen SP, Clauw D, Littlejohn G, Usui C, Hauser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397:2098–110.
pubmed: 34062144
doi: 10.1016/S0140-6736(21)00392-5
pmcid: 34062144
Kosek E, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382–6.
pubmed: 26835783
doi: 10.1097/j.pain.0000000000000507
pmcid: 26835783
Nicholas M, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28–37.
pubmed: 30586068
doi: 10.1097/j.pain.0000000000001390
pmcid: 30586068
Cella D, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010;63(11):1179–94.
pubmed: 20685078
pmcid: 2965562
doi: 10.1016/j.jclinepi.2010.04.011
Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–29.
pubmed: 27916278
doi: 10.1016/j.semarthrit.2016.08.012
pmcid: 27916278
Kroenke K, et al. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–21.
pubmed: 19996233
pmcid: 19996233
Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles M. Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep. 2017;2(3):e598.
pubmed: 29392213
pmcid: 5741304
doi: 10.1097/PR9.0000000000000598
Fitzcharles MA, et al. Canadian Pain Society and Canadian Rheumatology Association recommendations for rational care of persons with fibromyalgia. A summary report. J Rheumatol. 2013;40(8):1388–93.
pubmed: 23818709
doi: 10.3899/jrheum.130127
pmcid: 23818709
Ablin JN, et al. Guidelines for the diagnosis and treatment of the fibromyalgia syndrome. Harefuah. 2013;152(12):742–51 (In Hebrew).
pubmed: 24483001
pmcid: 24483001
Eich W, et al. Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis. Schmerz. 2012;26(3):247–58 (In German).
pubmed: 22760457
doi: 10.1007/s00482-012-1169-x
pmcid: 22760457
Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.
pubmed: 27377815
doi: 10.1136/annrheumdis-2016-209724
pmcid: 27377815
Goldenberg DL. Diagnosis and differential diagnosis of fibromyalgia. Am J Med. 2009;122(12 Suppl):S14–21.
pubmed: 19962492
doi: 10.1016/j.amjmed.2009.09.007
pmcid: 19962492
Melancia JL, Francisco AF, Antunes JL. Spinal stenosis. Handb Clin Neurol. 2014;119:541–9.
pubmed: 24365318
doi: 10.1016/B978-0-7020-4086-3.00035-7
pmcid: 24365318
Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373–87.
pubmed: 21342078
doi: 10.1517/14740338.2011.540568
pmcid: 21342078
Henry NL, et al. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer. 2010;116(18):4360–7.
pubmed: 20549827
doi: 10.1002/cncr.25385
pmcid: 20549827
Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96–110.
doi: 10.14310/horm.2002.1226
Sarzi-Puttini P, et al. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645–60.
pubmed: 33024295
doi: 10.1038/s41584-020-00506-w
Doppler K, et al. Reduced dermal nerve fiber diameter in skin biopsies of patients with fibromyalgia. Pain. 2015;156(11):2319–25.
pubmed: 26164586
doi: 10.1097/j.pain.0000000000000285
Peters MJ, et al. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology. 2013;81(15):1356–60.
pubmed: 23997150
doi: 10.1212/WNL.0b013e3182a8236e
Ryabkova VA, Churilov LP, Shoenfeld Y. Neuroimmunology: what role for autoimmunity, neuroinflammation, and small fiber neuropathy in fibromyalgia, chronic fatigue syndrome, and adverse events after human papillomavirus vaccination? Int J Mol Sci. 2019;20(20):5164.
pmcid: 6834318
doi: 10.3390/ijms20205164
pubmed: 6834318
Naugle KM, et al. Physical activity behavior predicts endogenous pain modulation in older adults. Pain. 2017;158(3):383–90.
pubmed: 28187102
doi: 10.1097/j.pain.0000000000000769
Clos-Garcia M, et al. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia. EBioMedicine. 2019;46:499–511.
pubmed: 31327695
pmcid: 6710987
doi: 10.1016/j.ebiom.2019.07.031
Wilmanski T, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab. 2021;3(2):274–86.
pubmed: 33619379
pmcid: 8169080
doi: 10.1038/s42255-021-00348-0
Freidin MB et al. An association between chronic widespread pain and the gut microbiome. Rheumatology (Oxford) (Epub 17 Dec 2020)
Minerbi A, Fitzcharles MA. Gut microbiome: pertinence in fibromyalgia. Clin Exp Rheumatol. 2020;38(Suppl 123):99–104.
pubmed: 32116215
Minerbi A, et al. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019;160(11):2589–602.
pubmed: 31219947
doi: 10.1097/j.pain.0000000000001640
pmcid: 31219947
Ablin J, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med. 2013;2013: 485272.
pubmed: 24348701
pmcid: 3856149
Fitzcharles MA, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. 2013;18(3):119–26.
pubmed: 23748251
pmcid: 3673928
doi: 10.1155/2013/918216
Petzke F, et al. General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):246–54 (In German).
pubmed: 28493229
doi: 10.1007/s00482-017-0201-6
Rossy LA, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21(2):180–91.
pubmed: 10499139
doi: 10.1007/BF02908299
Cosio D, Schafer T. Implementing an acceptance and commitment therapy group protocol with veterans using VA’s stepped care model of pain management. J Behav Med. 2015;38(6):984–97.
pubmed: 26174449
doi: 10.1007/s10865-015-9647-0
Mok A, et al. Physical activity trajectories and mortality: population based cohort study. BMJ. 2019;365:l2323.
pubmed: 31243014
pmcid: 6592407
doi: 10.1136/bmj.l2323
de Souto BP, et al. Association of long-term exercise training with risk of falls, fractures, hospitalizations, and mortality in older adults: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):394–405.
doi: 10.1001/jamainternmed.2018.5406
Karsdorp PA, Vlaeyen JW. Active avoidance but not activity pacing is associated with disability in fibromyalgia. Pain. 2009;147(1–3):29–35.
pubmed: 19716234
doi: 10.1016/j.pain.2009.07.019
Torres X, et al. Pain locus of control predicts return to work among Spanish fibromyalgia patients after completion of a multidisciplinary pain program. Gen Hosp Psychiatry. 2009;31(2):137–45.
pubmed: 19269534
doi: 10.1016/j.genhosppsych.2008.12.001
Malin K, Littlejohn GO. Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. J Pain Res. 2012;5:463–71.
pubmed: 23152697
pmcid: 3496525
García-Ríos MC, et al. Effectiveness of health education in patients with fibromyalgia: a systematic review. Eur J Phys Rehabil Med. 2019;55(2):301–13.
pubmed: 30698402
doi: 10.23736/S1973-9087.19.05524-2
pmcid: 30698402
Busch AJ, et al. Exercise therapy for fibromyalgia. Curr Pain Headache Rep. 2011;15(5):358–67.
pubmed: 21725900
pmcid: 3165132
doi: 10.1007/s11916-011-0214-2
Ellingson LD, et al. Physical activity, sustained sedentary behavior, and pain modulation in women with fibromyalgia. J Pain. 2012;13(2):195–206.
pubmed: 22245361
pmcid: 3272134
doi: 10.1016/j.jpain.2011.11.001
Soriano-Maldonado A, et al. Association of physical fitness with pain in women with fibromyalgia: the Al-Ándalus project. Arthritis Care Res (Hoboken). 2015;67(11):1561–70.
pubmed: 25939406
doi: 10.1002/acr.22610
pmcid: 25939406
Borges-Cosic M, et al. Sedentary time, physical activity, and sleep quality in fibromyalgia: the Al-Ándalus project. Scand J Med Sci Sports. 2019;29(2):266–74.
pubmed: 30306645
doi: 10.1111/sms.13318
pmcid: 30306645
Gavilán-Carrera B, et al. Patterns of sedentary time and quality of life in women with fibromyalgia: cross-sectional study from the Al-Ándalus project. JMIR Mhealth Uhealth. 2020;8(3): e14538.
pubmed: 32191211
pmcid: 7118547
doi: 10.2196/14538
Gavilán-Carrera B, et al. Association of objectively measured physical activity and sedentary time with health-related quality of life in women with fibromyalgia: the Al-Ándalus project. J Sport Health Sci. 2019;8(3):258–66.
pubmed: 31193271
doi: 10.1016/j.jshs.2018.07.001
pmcid: 31193271
Andrade A, Dominski FH, Sieczkowska SM. What we already know about the effects of exercise in patients with fibromyalgia: an umbrella review. Semin Arthritis Rheum. 2020;50(6):1465–80.
pubmed: 32147091
doi: 10.1016/j.semarthrit.2020.02.003
pmcid: 32147091
Winkelmann A. Is aerobic exercise training beneficial for adults with fibromyalgia? A cochrane review summary with commentary. Am J Phys Med Rehabil. 2019;98(2):169–70.
pubmed: 30422826
doi: 10.1097/PHM.0000000000001093
pmcid: 30422826
Estévez-López F, et al. Effectiveness of exercise on fatigue and sleep quality in fibromyalgia: a systematic review and meta-analysis of randomized trials. Arch Phys Med Rehabil. 2020;102(4):752–61.
pubmed: 32721388
doi: 10.1016/j.apmr.2020.06.019
pmcid: 32721388
Franco KFM, et al. Prescription of exercises for the treatment of chronic pain along the continuum of nociplastic pain: a systematic review with meta-analysis. Eur J Pain. 2021;25(1):51–70.
doi: 10.1002/ejp.1666
Fernandes G, et al. Swimming improves pain and functional capacity of patients with fibromyalgia: a randomized controlled trial. Arch Phys Med Rehabil. 2016;97(8):1269–75.
pubmed: 26903145
doi: 10.1016/j.apmr.2016.01.026
pmcid: 26903145
Verstappen FTJ, et al. Fitness characteristics of female patients with fibromyalgia. J Musculoskelet Pain. 1995;3(3):45–58.
doi: 10.1300/J094v03n03_04
Kaleth AS, Slaven JE, Ang DC. Does increasing steps per day predict improvement in physical function and pain interference in adults with fibromyalgia? Arthritis Care Res (Hoboken). 2014;66(12):1887–94.
pubmed: 25049001
pmcid: 4390054
doi: 10.1002/acr.22398
Kaleth AS, et al. Predictors of physical activity in patients with fibromyalgia: a path analysis. J Clin Rheumatol. 2020. https://doi.org/10.1097/RHU.0000000000001684 .
doi: 10.1097/RHU.0000000000001684
pubmed: 33337808
pmcid: 33337808
D’Onghia M, et al. Fibromyalgia and obesity: a comprehensive systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51(2):409–24.
pubmed: 33676126
doi: 10.1016/j.semarthrit.2021.02.007
pmcid: 33676126
Climent-Sanz C, et al. poor sleep quality experience and self-management strategies in fibromyalgia: a qualitative metasynthesis. J Clin Med. 2020;9(12):4000.
pmcid: 7763602
doi: 10.3390/jcm9124000
Tang NK, et al. Nonpharmacological treatments of insomnia for long-term painful conditions: a systematic review and meta-analysis of patient-reported outcomes in randomized controlled trials. Sleep. 2015;38(11):1751–64.
pubmed: 25902806
pmcid: 4813361
doi: 10.5665/sleep.5158
Antcliff D, et al. Activity pacing is associated with better and worse symptoms for patients with long-term conditions. Clin J Pain. 2017;33(3):205–14.
pubmed: 27322396
doi: 10.1097/AJP.0000000000000401
pmcid: 27322396
López-Rodríguez MM, et al. Patterns of food avoidance and eating behavior in women with fibromyalgia. Endocrinol Diabetes Nutr. 2017;64(9):480–90.
pubmed: 29050704
doi: 10.1016/j.endinu.2017.07.002
pmcid: 29050704
Silva AR, et al. Dietary interventions in fibromyalgia: a systematic review. Ann Med. 2019;51(Suppl 1):2–14.
pubmed: 30735059
pmcid: 7888848
doi: 10.1080/07853890.2018.1564360
Aman MM, et al. Evidence-based non-pharmacological therapies for fibromyalgia. Curr Pain Headache Rep. 2018;22(5):33.
pubmed: 29619620
doi: 10.1007/s11916-018-0688-2
pmcid: 29619620
Pagliai G, et al. Nutritional interventions in the management of fibromyalgia syndrome. Nutrients. 2020;12(9):2525.
pmcid: 7551285
doi: 10.3390/nu12092525
Slim M, et al. The effects of a gluten-free diet versus a hypocaloric diet among patients with fibromyalgia experiencing gluten sensitivity-like symptoms: a pilot, open-label randomized clinical trial. J Clin Gastroenterol. 2017;51(6):500–7.
pubmed: 27548732
doi: 10.1097/MCG.0000000000000651
pmcid: 27548732
Vellisca MY, Lator JI. Monosodium glutamate and aspartame in perceived pain in fibromyalgia. Rheumatol Int. 2014;34(7):1011–3.
pubmed: 23765203
doi: 10.1007/s00296-013-2801-5
pmcid: 23765203
Martínez-Rodríguez A, et al. Psychological and sleep effects of tryptophan and magnesium-enriched Mediterranean diet in women with fibromyalgia. Int J Environ Res Public Health. 2020;17(7):2227.
pmcid: 7178091
doi: 10.3390/ijerph17072227
Marum AP, et al. A low fermentable oligo-di-mono saccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients. Scand J Pain. 2016;13:166–72.
pubmed: 28850525
doi: 10.1016/j.sjpain.2016.07.004
pmcid: 28850525
Lowry E, et al. Dietary interventions in the management of fibromyalgia: a systematic review and best-evidence synthesis. Nutrients. 2020;12(9):2664.
pmcid: 7551150
doi: 10.3390/nu12092664
Elma Ö, et al. Do nutritional factors interact with chronic musculoskeletal pain? A systematic review. J Clin Med. 2020;9(3):702.
pmcid: 7141322
doi: 10.3390/jcm9030702
Arranz LI, Canela M, Rafecas M. Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. Rheumatol Int. 2012;32(9):2615–21.
pubmed: 21833524
doi: 10.1007/s00296-011-2010-z
pmcid: 21833524
Bernardy K, et al. Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Pain. 2018;22(2):242–60.
pubmed: 28984402
doi: 10.1002/ejp.1121
pmcid: 28984402
Lumley MA, et al. Emotional awareness and expression therapy, cognitive behavioral therapy, and education for fibromyalgia: a cluster-randomized controlled trial. Pain. 2017;158(12):2354–63.
pubmed: 28796118
pmcid: 5680092
doi: 10.1097/j.pain.0000000000001036
Langhorst J, et al. Efficacy of hydrotherapy in fibromyalgia syndrome—a meta-analysis of randomized controlled clinical trials. Rheumatology (Oxford). 2009;48(9):1155–9.
doi: 10.1093/rheumatology/kep182
McVeigh JG, et al. The effectiveness of hydrotherapy in the management of fibromyalgia syndrome: a systematic review. Rheumatol Int. 2008;29(2):119–30.
pubmed: 18751709
doi: 10.1007/s00296-008-0674-9
pmcid: 18751709
Baranowsky J, et al. Qualitative systemic review of randomized controlled trials on complementary and alternative medicine treatments in fibromyalgia. Rheumatol Int. 2009;30(1):1–21.
pubmed: 19672601
doi: 10.1007/s00296-009-0977-5
pmcid: 19672601
Perraton L, Machotka Z, Kumar S. Components of effective randomized controlled trials of hydrotherapy programs for fibromyalgia syndrome: a systematic review. J Pain Res. 2009;2:165–73.
pubmed: 21197303
pmcid: 3004626
doi: 10.2147/JPR.S8052
Ernst E. Chiropractic treatment for fibromyalgia: a systematic review. Clin Rheumatol. 2009;28(10):1175–8.
pubmed: 19544042
doi: 10.1007/s10067-009-1217-9
pmcid: 19544042
Schneider M, et al. Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. J Manip Physiol Ther. 2009;32(1):25–40.
doi: 10.1016/j.jmpt.2008.08.012
Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res. 1996;9(1):13–7.
pubmed: 8945108
doi: 10.1002/art.1790090105
pmcid: 8945108
Cao H, Liu J, Lewith GT. Traditional Chinese medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. J Altern Complement Med. 2010;16(4):397–409.
pubmed: 20423209
pmcid: 3110829
doi: 10.1089/acm.2009.0599
De Silva V, et al. Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology (Oxford). 2010;49(6):1063–8.
doi: 10.1093/rheumatology/keq025
Martin-Sanchez E, et al. Efficacy of acupuncture for the treatment of fibromyalgia: systematic review and meta-analysis of randomized trials. Open Rheumatol J. 2009;3:25–9.
pubmed: 19590596
pmcid: 2705855
doi: 10.2174/1874312900903010025
Mayhew E, Ernst E. Acupuncture for fibromyalgia—a systematic review of randomized clinical trials. Rheumatology (Oxford). 2007;46(5):801–4.
doi: 10.1093/rheumatology/kel406
Berman BM, et al. Is acupuncture effective in the treatment of fibromyalgia? J Fam Pract. 1999;48(3):213–8.
pubmed: 10086765
pmcid: 10086765
Langhorst J, et al. Efficacy of acupuncture in fibromyalgia syndrome—a systematic review with a meta-analysis of controlled clinical trials. Rheumatology. 2010;49(4):778–88.
pubmed: 20100789
doi: 10.1093/rheumatology/kep439
pmcid: 20100789
Deare JC, et al. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;2013(5):CD007070.
pmcid: 4105202
Perry R, Terry R, Ernst E. A systematic review of homoeopathy for the treatment of fibromyalgia. Clin Rheumatol. 2010;29(5):457–64.
pubmed: 20099019
doi: 10.1007/s10067-009-1361-2
pmcid: 20099019
Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571–84.
pubmed: 20015034
doi: 10.2174/092986710790416326
pmcid: 20015034
Hoel RW, Connolly RMG, Takahashi PY. Polypharmacy management in older patients. Mayo Clin Proc. 2021;96(1):242–56.
pubmed: 33413822
doi: 10.1016/j.mayocp.2020.06.012
pmcid: 33413822
American Geriatrics Society 2019 updated AGS beers Criteria
Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5(4):191–9.
pubmed: 19337283
doi: 10.1038/nrrheum.2009.25
pmcid: 19337283
Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract. 2008;8(3):177–89.
pubmed: 18363616
doi: 10.1111/j.1533-2500.2008.00190.x
pmcid: 18363616
Thorpe J, et al. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018;2(2):CD010585.
pubmed: 29457627
pmcid: 29457627
World Health Organization. WHO Pain Ladder. 1986. http://www.who.int/cancer/palliative/painladder/en/ . Accessed 22 Nov 2011
Bennett RM, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–45.
pubmed: 12753877
doi: 10.1016/S0002-9343(03)00116-5
pmcid: 12753877
What dose of paracetamol for older people? Drug Ther Bull. 2018;56(6):69–72
Bertolini A, et al. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006;12(3–4):250–75.
pubmed: 17227290
doi: 10.1111/j.1527-3458.2006.00250.x
pmcid: 17227290
Conaghan PG, et al. Safety of paracetamol in osteoarthritis: what does the literature say? Drugs Aging. 2019;36(Suppl 1):7–14.
pubmed: 31073920
pmcid: 6509082
doi: 10.1007/s40266-019-00658-9
Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc. 2011;142(1):38–44.
pubmed: 21193765
doi: 10.14219/jada.archive.2011.0026
pmcid: 21193765
Lynch ME, Watson CP. The pharmacotherapy of chronic pain: a review. Pain Res Manag. 2006;11(1):11–38.
pubmed: 16511612
pmcid: 2585035
doi: 10.1155/2006/642568
Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43(2):378–85.
pubmed: 10693878
doi: 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2
pmcid: 10693878
Derry S, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;3(3):CD012332.
pubmed: 28349517
pmcid: 28349517
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–13.
pubmed: 16376147
doi: 10.1016/j.coph.2005.11.003
pmcid: 16376147
Hauser W, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin—a meta-analysis of randomized controlled trials. Pain. 2009;145(1–2):69–81.
pubmed: 19539427
doi: 10.1016/j.pain.2009.05.014
pmcid: 19539427
Siler AC, et al. Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain. 2011;12(4):407–15.
pubmed: 21146466
doi: 10.1016/j.jpain.2010.09.007
pmcid: 21146466
Holtedahl R. Questionable documentation of the effect of pregabalin in fibromyalgia. Tidsskr Nor Laegeforen. 2010;130(10):1032–6 (In Norwegian).
pubmed: 20489805
doi: 10.4045/tidsskr.09.0576
pmcid: 20489805
Moore RA et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.
Derry S, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):CD011790.
pubmed: 27684492
pmcid: 27684492
Cooper TE, et al. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017;1(1):CD012188.
pubmed: 28045473
pmcid: 28045473
Randinitis EJ, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–83.
pubmed: 12638396
doi: 10.1177/0091270003251119
pmcid: 12638396
de Landaluce LO, et al. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf. 2018;41(12):1325–31.
doi: 10.1007/s40264-018-0695-6
Hauser W, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301(2):198–209.
pubmed: 19141768
doi: 10.1001/jama.2008.944
pmcid: 19141768
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;(4):CD007115
Choy EHS, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol. 2009;28(9):1035–44.
pubmed: 19533210
pmcid: 2721139
doi: 10.1007/s10067-009-1203-2
Welsch P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2(2):CD010292.
pubmed: 29489029
pmcid: 29489029
Gilron I, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016;157(7):1532–40.
pubmed: 26982602
doi: 10.1097/j.pain.0000000000000558
pmcid: 26982602
Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388–95.
pubmed: 15547167
doi: 10.1001/jama.292.19.2388
pmcid: 15547167
VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. J Clin Pharm Ther. 2015;40(1):1–6.
pubmed: 25294655
doi: 10.1111/jcpt.12216
pmcid: 25294655
Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012;41(5):646–52.
pubmed: 22743149
doi: 10.1093/ageing/afs072
pmcid: 22743149
Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41(2):104–13.
pubmed: 10749947
doi: 10.1176/appi.psy.41.2.104
pmcid: 10749947
Nishishinya B, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology. 2008;47(12):1741–6.
pubmed: 18697829
doi: 10.1093/rheumatology/ken317
pmcid: 18697829
Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Expert Rev Neurother. 2015;15(10):1123–50.
pubmed: 26395929
doi: 10.1586/14737175.2015.1091726
pmcid: 26395929
Welsch P, et al. Mirtazapine for fibromyalgia in adults. Cochrane Database Syst Rev. 2018;8(8):CD012708.
pubmed: 30080242
pmcid: 30080242
Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51(1):9–13.
pubmed: 14872449
doi: 10.1002/art.20076
pmcid: 14872449
Moldofsky H, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38(12):2653–63.
pubmed: 21885490
doi: 10.3899/jrheum.110194
pmcid: 21885490
Goldenberg DL, et al. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640–8.
pubmed: 26975749
doi: 10.1016/j.mayocp.2016.02.002
pmcid: 26975749
Gaskell H, et al. Oxycodone for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):CD012329.
pubmed: 27582266
pmcid: 27582266
Zeng C, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA. 2019;321(10):969–82.
pubmed: 30860559
pmcid: 6439672
doi: 10.1001/jama.2019.1347
Bruun-Plesner K, et al. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose–response relationships. Pain Med. 2020;21(10):2253–61.
pubmed: 32068870
doi: 10.1093/pm/pnaa001
pmcid: 32068870
Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–38.
pubmed: 23359310
doi: 10.1002/art.37734
pmcid: 23359310
Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–72.
pubmed: 19453963
doi: 10.1111/j.1526-4637.2009.00613.x
pmcid: 19453963
Sarzi-Puttini P, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. 2019;15(10):1019–32.
pubmed: 31512536
doi: 10.1080/1744666X.2019.1665997
pmcid: 31512536
Baumeister D, et al. Plasma parameters of the endocannabinoid system are unaltered in fibromyalgia. Psychother Psychosom. 2018;87(6):377–9.
pubmed: 30257256
doi: 10.1159/000492600
pmcid: 30257256
Ste-Marie PA, et al. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012;64(8):1202–8.
pubmed: 22730275
doi: 10.1002/acr.21732
pmcid: 22730275
van de Donk T, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860–9.
pubmed: 30585986
doi: 10.1097/j.pain.0000000000001464
pmcid: 30585986
Fiz J, et al. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE. 2011;6(4):e18440.
pubmed: 21533029
pmcid: 3080871
doi: 10.1371/journal.pone.0018440
Habib G, Artul S. Medical cannabis for the treatment of fibromyalgia. J Clin Rheumatol. 2018;24(5):255–8.
pubmed: 29461346
doi: 10.1097/RHU.0000000000000702
pmcid: 29461346
Sagy I, et al. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6):807.
pmcid: 6616435
doi: 10.3390/jcm8060807
Beauchet O. Medical cannabis use in older patients: update on medical knowledge. Maturitas. 2018;118:56–9.
pubmed: 30415756
doi: 10.1016/j.maturitas.2018.10.010
pmcid: 30415756
Levy C, Galenbeck E, Magid K. Cannabis for symptom management in older adults. Med Clin N Am. 2020;104(3):471–89.
pubmed: 32312410
doi: 10.1016/j.mcna.2020.01.004
pmcid: 32312410
Minerbi A, Häuser W, Fitzcharles MA. Medical cannabis for older patients. Drugs Aging. 2019;36(1):39–51.
pubmed: 30488174
doi: 10.1007/s40266-018-0616-5
pmcid: 30488174
Olivan-Blázquez B, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain. 2014;155(12):2517–25.
pubmed: 25218600
doi: 10.1016/j.pain.2014.09.004
pmcid: 25218600
Littlejohn G, Guymer E. Modulation of NMDA receptor activity in fibromyalgia. Biomedicines. 2017;5(2):15.
pmcid: 5489801
doi: 10.3390/biomedicines5020015
Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52(8):2495–505.
pubmed: 16052595
doi: 10.1002/art.21191
Wu Y, et al. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology. 2004;47(8):1146–56.
pubmed: 15567424
doi: 10.1016/j.neuropharm.2004.08.019
Perrot S, Russell IJ. More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: a meta-analysis examining six core symptoms. Eur J Pain. 2014;18(8):1067–80.
pubmed: 25139817
doi: 10.1002/ejp.564
Wilderman I, et al. Repeated intravenous lidocaine infusions for patients with fibromyalgia: higher doses of lidocaine have a stronger and longer-lasting effect on pain reduction. Pain Med. 2020;21(6):1230–9.
pubmed: 31621870
doi: 10.1093/pm/pnz251
McCleane G. Does intravenous lidocaine reduce fibromyalgia pain? A randomized, double-blind, placebo controlled cross-over study. Pain Clin. 2000;12(3):181–5.
doi: 10.1163/156856900750232515
Staud R, et al. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain. 2009;145(1–2):96–104.
pubmed: 19540671
pmcid: 2751583
doi: 10.1016/j.pain.2009.05.020
Affaitati G, et al. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2011;15(1):61–9.
pubmed: 20889359
doi: 10.1016/j.ejpain.2010.09.002
Castro-Sanchez AM, et al. Effects of myofascial release techniques on pain, physical function, and postural stability in patients with fibromyalgia: a randomized controlled trial. Clin Rehabil. 2011;25(9):800–13.
pubmed: 21673013
doi: 10.1177/0269215511399476
pmcid: 21673013
Ko GD, et al. Effective pain palliation in fibromyalgia syndrome patients with botulinum toxin type-A: case series of 25. J Musculoskelet Pain. 2007;15(4):55–66.
doi: 10.1300/J094v15n04_07
Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord. 1996;11(4):459.
pubmed: 8813236
doi: 10.1002/mds.870110425
Jacobson SA, et al. Characterization of fibromyalgia symptoms in patients 55–95 years old: a longitudinal study showing symptom persistence with suboptimal treatment. Aging Clin Exp Res. 2015;27(1):75–82.
pubmed: 24859821
doi: 10.1007/s40520-014-0238-7
pmcid: 24859821
Campos RP, Vazquez MI. Health-related quality of life in women with fibromyalgia: clinical and psychological factors associated. Clin Rheumatol. 2012;31(2):347–55.
pubmed: 21979445
doi: 10.1007/s10067-011-1870-7
pmcid: 21979445
Wolfe F, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum. 1997;40(9):1571–9.
pubmed: 9324010
doi: 10.1002/art.1780400905
pmcid: 9324010
Walitt B, et al. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011;38(10):2238–46.
pubmed: 21765102
doi: 10.3899/jrheum.110026
Martinez MP, et al. The relationship between the fear-avoidance model of pain and personality traits in fibromyalgia patients. J Clin Psychol Med Settings. 2011;18(4):380–91.
pubmed: 21964824
doi: 10.1007/s10880-011-9263-2
Kim CH, et al. The association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012;64(2):222–8.
pubmed: 21972124
doi: 10.1002/acr.20653
Redelmeier DA, et al. Fibromyalgia and the risk of a subsequent motor vehicle crash. J Rheumatol. 2015;42(8):1502–10.
pubmed: 25979716
doi: 10.3899/jrheum.141315